Eleven Bedlington terriers were found to have a mean hepatic copper concentration of 6,321 micrograms/g dry wt (normal, 200 micrograms/g dry wt) and renal copper concentration that was three or four times normal. Brain copper levels were normal in younger dogs, were elevated in two older dogs, and were 100 times normal in one dog that died of the disease. Increased concentrations of copper in the liver, kidney, and brain also characterize Wilson's disease. Erythrocyte survival was normal in three affected dogs, but serum glutamic-pyruvic transaminase levels were usually elevated. Unlike the hypoceruloplasminemia of patients with Wilson's disease, plasma ceruloplasmin activity was not only normal but was also slightly elevated in the terriers. Despite their normal or excessive ceruloplasmin, the Bedlington terriers could convert ionic 64Cu to radioceruloplasmin but did so only very slowly. These dogs accumulated significantly more 64Cu in their livers than normal, much like patients with Wilson's disease do before symptoms develop.

Background: The aim of the present study was to investigate the effect of brewer's yeast on plasma glucose and lipid profiles in patients with type 2 diabetes (T2D). Methods: The present semi-experimental study was performed on 55 T2D patients with hypercholesterolemia. All patients received 12 tablets of 300 mg yeast per day for 8 weeks. Each tablet contained 1.2 lg chromium. Fasting plasma glucose, total cholesterol, high-density lipoproteincholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and triglyceride levels were measured at baseline and then again at Weeks 4 and 8. Results: Although there was a tendency for plasma glucose levels to decrease at Week 4, the difference failed to reach statistical significance (P = 0.065). However, after 8 weeks, the decrease in plasma glucose was significant (P = 0.043). Again, although there was a tendency for decreased plasma cholesterol at Week 8 compared with baseline, the difference failed to reach statistical significance (215 ± 29 vs 226 ± 37 mg ⁄ dL, respectively; P = 0.056). Brewer's yeast significantly decreased plasma triglyceride and LDL-C levels at Weeks 4 and 8. In contrast, plasma HDL-C levels were significantly increased at both 4 and 8 weeks compared with baseline (41.3 ± 8.8 and 43.3 ± 7.5 vs 36 ± 5 mg ⁄ dL, respectively; P < 0.01 and P < 0.01, respectively). Conclusion: In conclusion, the consumption of brewer's yeast over a period of 8 weeks may improve cardiometabolic risk factors in T2D patients. However, these findings need to be confirmed in a large double-blind clinical trial.